What we are researching
The purpose of this study is to find out how well the study medicine works in helping people, who have excess body weight and obstructive sleep apnea not treated with positive airway pressure, lose weight and improve their sleep apnea.
Who may participate
Each clinical trial has its own requirements for who can participate, often called eligibility criteria. Some of the key criteria for this study are listed here. Discuss these requirements with your study doctor to determine if you may be eligible to participate. Additional criteria for your doctor to review can be found here NCT07571005.
Overweight or Obesity
Have a body mass index (BMI) of 27 or higher
Obstructive Sleep Apnea (OSA)
Have been diagnosed with moderate-to-severe OSA, with an AHI score of 15 or more events per hour
No use of positive airway pressure (PAP) for at least 4 weeks before joining the study
Type 1 or 2 diabetes
Have not been diagnosed with type 1 or type 2 diabetes
Age
18+ years
Study Medicine
Once weekly injection
Number of study visits
About 24 visits over a period of about 21 months
What to expect
If your study doctor determines that you are eligible and you decide to participate, you will be enrolled into the study.
Once enrolled, you will be randomly assigned to receive either the study medicine at one of two dose levels or placebo (which has no active medicine in it). All are given as injections under the skin, using an injection pen. Your study team will teach you how to use the injection pen.
Your participation is expected to last about 1 year and 9 months, with a mix of in-person and phone visits every 4 weeks. Visits may include physical exams, lab tests and questionnaires to monitor your health and safety.
Call 866-867-7178 or email clinicaltrials@novonordisk.com to learn more
about the study and find out whether there is a participating study site near you.
When you call, please reference study 8025 or AMAZE 3
You may also choose to discuss this clinical trial with your healthcare provider.